These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 29162041

  • 1. Does anthracycline-based chemotherapy in pregnant women with cancer offer safe cardiac and neurodevelopmental outcomes for the developing fetus?
    Framarino-Dei-Malatesta M, Sammartino P, Napoli A.
    BMC Cancer; 2017 Nov 21; 17(1):777. PubMed ID: 29162041
    [Abstract] [Full Text] [Related]

  • 2. Cardioprotective effect of Platycodon grandiflorum in patients with early breast cancer receiving anthracycline-based chemotherapy: study protocol for a randomized controlled trial.
    Hao W, Liu S, Qin Y, Sun C, Chen L, Wu C, Bao Y.
    Trials; 2017 Aug 22; 18(1):386. PubMed ID: 28830541
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
    Schuler MK, Gerdes S, West A, Richter S, Busemann C, Hentschel L, Lenz F, Kopp HG, Ehninger G, Reichardt P, Pink D.
    BMC Cancer; 2016 Aug 09; 16():619. PubMed ID: 27507014
    [Abstract] [Full Text] [Related]

  • 4. Chemotherapy during pregnancy: effect of anthracyclines on fetal and maternal cardiac function.
    Gziri MM, Debiève F, DE Catte L, Mertens L, Barrea C, VAN Calsteren K, Han SN, Heyns L, Amant F.
    Acta Obstet Gynecol Scand; 2012 Dec 09; 91(12):1465-8. PubMed ID: 22880883
    [Abstract] [Full Text] [Related]

  • 5. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
    Antunes P, Esteves D, Nunes C, Sampaio F, Ascensão A, Vilela E, Teixeira M, Amarelo AL, Joaquim A.
    Trials; 2019 Jul 15; 20(1):433. PubMed ID: 31307527
    [Abstract] [Full Text] [Related]

  • 6. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D, Indolfi P, Casale F, Martino V, Di Tullio MT, Calabrò R.
    Paediatr Drugs; 2005 Jul 15; 7(2):67-76. PubMed ID: 15871628
    [Abstract] [Full Text] [Related]

  • 7. Chemotherapy-induced cardiotoxicity in children.
    Bansal N, Amdani S, Lipshultz ER, Lipshultz SE.
    Expert Opin Drug Metab Toxicol; 2017 Aug 15; 13(8):817-832. PubMed ID: 28679288
    [Abstract] [Full Text] [Related]

  • 8. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF, Mukku RB, Verma S, Liu JE, Oeffinger KC, Steingart RM, Hudis CA, Dang CT.
    Breast Cancer Res Treat; 2017 Nov 15; 166(1):241-247. PubMed ID: 28710537
    [Abstract] [Full Text] [Related]

  • 9. Cardiac toxicity after anthracycline chemotherapy in childhood.
    Iarussi D, Indolfi P, Galderisi M, Bossone E.
    Herz; 2000 Nov 15; 25(7):676-88. PubMed ID: 11141677
    [Abstract] [Full Text] [Related]

  • 10. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
    Rayson D, Richel D, Chia S, Jackisch C, van der Vegt S, Suter T.
    Ann Oncol; 2008 Sep 15; 19(9):1530-9. PubMed ID: 18480068
    [Abstract] [Full Text] [Related]

  • 11. Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.
    Kotwinski P, Smith G, Cooper J, Sanders J, Ma L, Teis A, Kotwinski D, Mythen M, Pennell DJ, Jones A, Montgomery H, Breast cancer Early disease: Toxicity from Therapy with Epirubicin Regimens–Cardiac Assessment and Risk Evaluation (BETTER-CARE) Study Investigators.
    PLoS One; 2016 Sep 15; 11(12):e0165262. PubMed ID: 27911951
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients.
    Broeyer FJ, Osanto S, Suzuki J, de Jongh F, van Slooten H, Tanis BC, Bruning T, Bax JJ, Ritsema van Eck HJ, de Kam ML, Cohen AF, Mituzhima Y, Burggraaf J.
    Br J Clin Pharmacol; 2014 Nov 15; 78(5):950-60. PubMed ID: 24844787
    [Abstract] [Full Text] [Related]

  • 13. Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer.
    Kirkham AA, Paterson DI, Prado CM, Mackey JR, Courneya KS, Pituskin E, Thompson RB.
    BMC Cancer; 2018 Sep 03; 18(1):864. PubMed ID: 30176834
    [Abstract] [Full Text] [Related]

  • 14. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    Arciniegas Calle MC, Sandhu NP, Xia H, Cha SS, Pellikka PA, Ye Z, Herrmann J, Villarraga HR.
    BMC Cancer; 2018 Oct 25; 18(1):1037. PubMed ID: 30359235
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic considerations in the use of anticancer drugs during pregnancy: challenges and new developments.
    Bell DJ, Kerr DJ.
    Expert Opin Drug Metab Toxicol; 2015 Oct 25; 11(9):1341-4. PubMed ID: 26065877
    [Abstract] [Full Text] [Related]

  • 16. The role of anthracyclines in the treatment of early breast cancer.
    Greene J, Hennessy B.
    J Oncol Pharm Pract; 2015 Jun 25; 21(3):201-12. PubMed ID: 24769570
    [Abstract] [Full Text] [Related]

  • 17. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L, Bramwell V, Moran LA.
    Cancer Prev Control; 1999 Apr 25; 3(2):145-59. PubMed ID: 10474762
    [Abstract] [Full Text] [Related]

  • 18. Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review.
    Jasra S, Anampa J.
    Curr Treat Options Oncol; 2018 May 11; 19(6):30. PubMed ID: 29752560
    [Abstract] [Full Text] [Related]

  • 19. High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury.
    Jones M, O'Gorman P, Kelly C, Mahon N, Fitzgibbon MC.
    Ann Clin Biochem; 2017 Jan 11; 54(1):149-157. PubMed ID: 27170025
    [Abstract] [Full Text] [Related]

  • 20. A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.
    Sabnis HS, Minson KA, Monroe C, Allen K, Metts JL, Cooper TM, Woods WG, Castellino SM, Keller FG.
    Leuk Res; 2020 Sep 11; 96():106421. PubMed ID: 32683126
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.